(Q43871392)

English

Ethinyl estradiol-drospirenone vs ethinyl estradiol-drospirenone plus metformin in the treatment of lean women with polycystic ovary syndrome

scientific article published in March 2013

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Ethinyl estradiol-drospirenone vs ethinyl estradiol-drospirenone plus metformin in the treatment of lean women with polycystic ovary syndrome (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

polycystic ovary syndrome

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

polycystic ovary

1 reference

based on heuristic

inferred from title

Bulent Okan Yildiz

1 reference

ORCID Public Data File 2021

author name string

Nese Cinar

1

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Ayla Harmanci

2

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Miyase Bayraktar

3

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Bulent O Yildiz

4

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

publication date

1 March 2013

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Clinical Endocrinology

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

78

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

379-384

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Polycystic Ovary Syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04415.X

21 January 2018

Polycystic ovary syndrome and cardiovascular disease: a premature association?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04415.X

21 January 2018

Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04415.X

21 January 2018

Oral contraceptives in polycystic ovary syndrome: risk-benefit assessment

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04415.X

21 January 2018

Combined oral contraceptives in the treatment of polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04415.X

21 January 2018

Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04415.X

21 January 2018

Drospirenone and cardiovascular risk in lean and obese polycystic ovary syndrome patients: a pilot study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04415.X

21 January 2018

Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04415.X

21 January 2018

Metformin in polycystic ovary syndrome: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04415.X

21 January 2018

Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04415.X

21 January 2018

Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04415.X

21 January 2018

Effects of metformin with or without supplementation with folate on homocysteine levels and vascular endothelium of women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04415.X

21 January 2018

Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04415.X

21 January 2018

Metformin administration improves leukocyte count in women with polycystic ovary syndrome: a 6-month prospective study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04415.X

21 January 2018

Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04415.X

21 January 2018

Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04415.X

21 January 2018

Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled cross-over trial.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04415.X

21 January 2018

The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04415.X

21 January 2018

Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04415.X

21 January 2018

Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04415.X

21 January 2018

Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04415.X

21 January 2018

Increased circulating soluble P-selectin in polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04415.X

21 January 2018

Drospirenone/ethinyl estradiol versus rosiglitazone treatment in overweight adolescents with polycystic ovary syndrome: comparison of metabolic, hormonal, and cardiovascular risk factors.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04415.X

21 January 2018

Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04415.X

21 January 2018

The effect of metformin treatment for 2 years without caloric restriction on endocrine and metabolic parameters in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04415.X

21 January 2018

Metformin versus oral contraceptive pill in polycystic ovary syndrome: a Cochrane review

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04415.X

21 January 2018

Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04415.X

21 January 2018

Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04415.X

21 January 2018

Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04415.X

21 January 2018

Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04415.X

21 January 2018

Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04415.X

21 January 2018

Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04415.X

21 January 2018

Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04415.X

21 January 2018

Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2012.04415.X

21 January 2018

Identifiers

10.1111/J.1365-2265.2012.04415.X

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43871392&oldid=2104062326"